Lipid nanoparticles, nucleic acid medicine and application

Through the design of new lipid nanoparticles, including NKT agonists and specific lipid components, NKT cells were successfully activated, solving the problem of poor tumor immunotherapy effects in the prior art and achieving stronger tumor treatment effects.

CN119015257APending Publication Date: 2024-11-26SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410926797.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-07-13
Filing Date
2024-07-11
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing lipid nanoparticles are difficult to effectively activate NKT cells, resulting in poor tumor immunotherapy.

Method used

Develop a novel lipid nanoparticle containing cationic lipids, structural lipids, auxiliary lipids, polymer-bound lipids and NKT agonists, especially α-galactose ceramide or its derivatives, through microfluidic devices Mixed and purified ultrafiltration to form a drug carrier that encapsulates therapeutic mRNA.

Benefits of technology

This new lipid nanoparticle can not only effectively deliver therapeutic mRNA, activate specific T cells and NKT cells immune responses, significantly upregulate gamma-interferon and granomycin B, enhance nonspecific immune killing and improve tumor treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015257A_ABST
    Figure CN119015257A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to lipid nanoparticles, a nucleic acid medicine and application. The invention provides a novel lipid nanoparticle, the nanoparticle comprises a novel component alpha-Galcer or an analogue thereof, the novel LNP not only can deliver a therapeutic mRNA (messenger ribonucleic acid) drug to provide a specific immunotherapy effect in a body, but also can further activate NKT toxic killer cells, so that the NKT toxic killer cells can be further activated. The NKT toxic cells further exert a non-specific immune killing effect, and the NKT toxic cells and the NKT toxic cells cooperatively kill tumors and exert a stronger tumor treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention claims the priority of the Chinese patent application filed with the Chinese Patent Office on July 13, 2023, with application number 2023108602959 and invention name “Lipid Nanoparticles, Nucleic Acid Drugs and Applications”, the entire contents of which are incorporated by reference into the present invention. Technical Field

[0002] The present invention relates to the field of medical technology, and in particular to lipid nanoparticles and nucleic acid drugs and applications thereof. Background Art

[0003] Lipid nanoparticles (LNPs) are a new type of drug delivery system for oligonucleotide drugs that overcomes their delivery difficulties. They are usually composed of amino lipids, steroids, neutral lipids, and polymer-bound lipids. They have the functions of providing protection against serum nucleases, inducing immune responses, and targeting specific cells or tissues.

[0004] NKT cells refer to a type of natural killer cells that are dependent on CD1d and highly reactive to α-Galcer. The functions of NKT cells mainly include direct cytotoxicity, indirect cytotoxicity, induction of immune memory and regulation of immunosuppression. Direct cytotoxicity refers to the activation of NKT after recognizing glycolipid antigens (such as α-Galcer) presented on tumor cells, releasing granulamycin B, perforin, etc. for direct killing. The indirect effects are mainly recruitment and induction of DC maturation. Inducing immune memory mainly involves the proliferation of primary and memory CD8+ T cells and the promotion of the increase of CD62L+NKT with longer functional duration. The regulation of immunosuppression is to inhibit the number and function of myeloid-derived immunosuppressive cells, co-localize and dissolve TAM, etc. The generation of NKT-induced immune memory and the regulation of immunosuppression are crucial for lasting anti-tumor immune response and preventing tumor recurrence. Summary of the invention

[0005] The present invention provides a novel lipid nanoparticle for treating tumors, which encapsulates therapeutic mRNA drugs and can activate specific T cell immune responses and NKT cell immune responses.

[0006] Specifically, the technical solution of the present invention is as follows: In a first aspect, the present invention provides a lipid nanoparticle comprising: (a) Cationic lipids; (b) structural lipids; (c) helper lipids; (d) polymer-bound lipids; (e) immune adjuvants; The immune adjuvant includes a NKT agonist; The NKT agonist is selected from at least one of α-galactosylceramide or its functional derivatives; The molar percentage of the immune adjuvant in the lipid nanoparticles is 0.3-5%.

[0007] Preferably, the molar ratio of the cationic lipid to the immune adjuvant is 30-60:1-5; preferably 45-55:1-5.

[0008] Preferably, the cationic lipid is selected from MC3, SM-102, ALC0315, DOTAP, DLinDMA, DLinkC2DMA, cKK-E12, A1A3, imidazole, HGT5000, HGT5001, OF-02, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, CLinDMA, CpLinDMA, DMOBA, DOcarbDAP, DLinDAP, DLincarbDAP, DLinCDAP, KLin-K-DMA, DLin-K-XTC2-DMA, HGT4003, C12-200, the cationic liposomes described in Patent Publication No. CN114105799B, and the cationic liposomes described in Patent Publication No. CN113461577B.

[0009] More preferably, the cationic lipid is selected from the cationic liposome described in Patent Publication No. CN114105799B and / or the cationic liposome described in Patent Publication No. CN113461577B.

[0010] Preferably, the molar ratio of the structural lipid to the immune adjuvant is 15-50:1-5.

[0011] Preferably, the structured lipid is selected from one or more of cholesterol, cholesterol ester, sterol hormones, sterol vitamins and phytosterols.

[0012] More preferably, the structured lipid is selected from one or more of cholesterol and its derivatives, cholesterol esters and phytosterols.

[0013] More preferably, the structured lipid is selected from cholesterol.

[0014] Preferably, the molar ratio of the auxiliary lipid to the immune adjuvant is 5-20:1-5.

[0015] Preferably, the helper lipid is selected from one or more of DSPC, DOPC, DPPG, DOPS and DOPE.

[0016] More preferably, the helper lipid is selected from DSPC and / or DOPS.

[0017] More preferably, the helper lipid is selected from DSPC.

[0018] Preferably, the molar ratio of the polymer-bound lipid to the immune adjuvant is 1-10:1-5.

[0019] Preferably, the polymer-bound lipid is selected from a lipid modified by PEG or its derivatives. For example, the polymer-bound lipid can be selected from one or more of DAG-PEG, DAA-PEG, DMG-PEG, Cer-PEG and DSPE-PEG.

[0020] In the present invention, the relative molecular mass of the PEG or its derivatives is preferably 2000-5000, more preferably 2000, 3000, 4000 or 5000.

[0021] The present invention does not particularly limit the specific sources of the above-mentioned raw material components, and any raw material products conventionally available on the market and meeting the general standards in the field can be used.

[0022] In a second aspect, the present invention provides the use of the lipid nanoparticles in biological immune activation, which includes NKT cell activation.

[0023] In a third aspect, the present invention provides use of the lipid nanoparticles as a drug delivery carrier.

[0024] In a fourth aspect, the present invention provides a nucleic acid drug comprising the lipid nanoparticles and therapeutic mRNA; the therapeutic mRNA is encapsulated in the lipid nanoparticles.

[0025] In the present invention, the therapeutic mRNA may be selected from but not limited to E7-mRNA and OVA-mRNA.

[0026] In a more specific embodiment provided by the present invention, the OVA antigen sequence is as follows: OVA-mRNA (SEQ ID NO: 1):

[0027] OVA-AA (SEQ ID NO:2): MGSIGAASMEFCFDVFKELKVHHANENIFYCPIAIMSALAMVYLGAKDSTRTQINKVVRFDKLPGFGDSIEAQCGTSVNVHSSLRDILNQITKPNDVYSFSLASRLYAEERYPILPEYLQCVKELYRGGLEPINFQTAADQARELINSWVESQTNGIIRNVLQPSSVDSQTAMVLVNAIVFKGLWEKAFKDEDTQAMPFRVTEQESKPVQMMYQIGLFRVASMASEKMKILELPFASGTMSMLVLLPDEVSGLEQLESIINFEKLTEWTSSNVMEERKIKVYLPRMKMEEKYNLTSVLMAMGITDVFSSSANLSGISSAESLKISQAVHAAHAEINEAGREVVGSAEAGVDAASVSEEFRADHPFLFCIKHIATNAVLFFGRCVSP**。

[0028] In a more specific embodiment provided by the present invention, the E7 antigen sequence is specifically as follows: E7-mRNA (SEQ ID NO:3): AUGCACGGCGACACCCCCACCCUGCACGAGUACAUGCUGGACCUGCAGCCCGAGACAACCGACCUGUACUGCUACGAGCAGCUGAACGACAGCAGCGAGGAGGAGGACGAGAUCGACGGCCCCGCCGGCCAGGCCGAGCCCGACAGAGCCCACUACAACAUCGUGACCUUCUGCUGCAAGUGCGACAGCACCCUGAGACUGUGCGUGCAGAGCACCCACGUGGACAUCAGAACCCUGGAGGACCUGCUGAUGGGCACCCUGGGCAUCGUGUGCCCCAUCUGCAGCCAGAAGCCCUGAUGA。

[0029] E7-AA (SEQ ID NO:4): MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP**.

[0030] Preferably, the therapeutic mRNA encodes a tumor-associated antigen.

[0031] Preferably, the therapeutic mRNA encodes an immunomodulatory molecule.

[0032] Preferably, the therapeutic mRNA encodes a tumor-associated antigen linked to an immunomodulatory molecule.

[0033] Preferably, the therapeutic mRNA encoding tumor-associated antigens and immune regulatory molecules are connected via a Linker.

[0034] Preferably, the sequence of the therapeutic mRNA is codon optimized.

[0035] Preferably, the therapeutic mRNA comprises a nucleic acid sequence encoding a signal peptide.

[0036] Preferably, the therapeutic mRNA includes a 5' untranslated region and / or a 3' untranslated region.

[0037] Preferably, the therapeutic mRNA comprises a modification of the 5' untranslated region, wherein the modification comprises a 5' cap structure.

[0038] Preferably, the therapeutic mRNA comprises a modification in the 3' untranslated region, wherein the modification comprises a polyA tail.

[0039] Preferably, the therapeutic mRNA comprises a linker sequence of one or more consecutive nucleotides.

[0040] Preferably, the therapeutic mRNA comprises one or more subgenomic promoters.

[0041] Preferably, the therapeutic mRNA is a closed circular molecule or a linear molecule.

[0042] Preferably, the dosage form of the nucleic acid drug is an injection, a lyophilized agent, a spray or a patch.

[0043] In a fifth aspect, the present invention provides a method for preparing the nucleic acid drug, dissolving the lipid nanoparticles in anhydrous ethanol to obtain an ethanol phase; dissolving the therapeutic mRNA in water to obtain an aqueous phase; mixing the ethanol phase and the aqueous phase to obtain the nucleic acid drug.

[0044] Preferably, the volume ratio of the ethanol phase to the aqueous phase is 1:3.

[0045] Preferably, the ethanol phase and the aqueous phase are mixed by a microfluidic device, and the total liquid flow rate of the ethanol phase and the aqueous phase is 12 L / Min; the mixing temperature of the ethanol phase and the aqueous phase is 25°C.

[0046] Preferably, after the mixing, ultrafiltration purification is also included, and the filter specification of the ultrafiltration purification is 100KD.

[0047] In a sixth aspect, the present invention provides a pharmaceutical composition comprising the nucleic acid drug, or the nucleic acid drug prepared by the preparation method; and further comprising: an immune checkpoint inhibitor.

[0048] Preferably, the immune checkpoint inhibitor is selected from one or more of anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies and anti-LAG3 antibodies.

[0049] In a seventh aspect, the present invention provides the use of the lipid nanoparticles, or the nucleic acid drug, or the nucleic acid drug prepared by the preparation method, or the pharmaceutical composition in treating tumors.

[0050] Preferably, the tumor includes at least one of cervical cancer, pancreatic cancer, renal cell carcinoma, colorectal cancer, liver cancer and brain glioma.

[0051] Preferably, the application includes at least one of the following forms: (1) The nucleic acid drug is used in combination with radical surgery to treat tumors; (2) The nucleic acid drug and chemotherapy drug are used in combination to treat tumors; (3) The nucleic acid drug and antibody-drug conjugate are used in combination to treat tumors; (4) The nucleic acid drug and the antibody-conjugated radioactive drug are used in combination to treat tumors.

[0052] Beneficial effects: The present invention provides a new lipid nanoparticle, which includes a new component of α-Galcer or its analogs. In addition to being able to deliver therapeutic mRNA drugs to the body to provide specific immunotherapy effects, the new LNP can further activate NKT toxic killer cells. The γ-interferon and granulamycin B that NKT cells use to kill tumors are significantly upregulated, and the NKT toxic cells further play a nonspecific immune killing role. The two work together to kill tumors and exert a stronger tumor treatment effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the drawings required for use in the embodiments or the description of the prior art will be described below.

[0054] Figure 1 This is the result of identifying the induced purity of BMDC in Example 6 of the present invention.

[0055] Figure 2 The encapsulation efficiency, particle size, and potential parameter results of the novel lipid nanoparticles in Example 5 of the present invention are shown in Figure A. Figure A shows the particle size and polymer dispersibility index of lipid nanoparticles containing different proportions of Galcer, and Figure B shows the potential and encapsulation efficiency of lipid nanoparticles containing different proportions of Galcer.

[0056] Figure 3 It is a ratio diagram of each component in the novel lipid nanoparticles in Example 5 of the present invention. Among them, Figure A shows the ratio diagram of each component detected by high performance liquid chromatography of the five-component LNP, and Figure B shows the molar percentage bar chart of each component in the theoretical and actual detection lipid nanoparticles.

[0057] Figure 4 This is a diagram of mRNA integrity detection in Galcer lipid nanoparticles in Example 5 of the present invention.

[0058] Figure 5 The results of the effects of mRNA-novel LNP drugs containing different ratios of Galcer on BMDC apoptosis in Example 6 of the present invention are shown in Figure A. Figure A shows a bar graph of BMDC apoptosis ratio, and Figure B shows a flow cytometry graph of BMDC apoptosis.

[0059] Figure 6 This is a time curve diagram of mRNA expression after the new nanoparticles in Example 6 of the present invention deliver Luciferase-mRNA in BMDC and DC2.4.

[0060] Figure 7 This is a detection diagram of the α-Galcer-CD1d complex generated after the novel lipid nanoparticles containing different ratios of Galcer in Example 6 of the present invention were delivered into DCs.

[0061] Figure 8 These are the test results of the new lipid nanoparticles in Example 6 of the present invention in presenting H2-Kb to the cell surface, BMDC maturation and activation, and function.

[0062] Fig. 9 This is the organ tissue staining and blood biochemical index detection results after the new lipid nanoparticles in Example 7 of the present invention delivered mRNA to mice.

[0063] Fig.10 These are the analysis results of various cell subpopulations after the novel lipid nanoparticles in Example 8 of the present invention delivered mRNA into mice.

[0064] Fig.11The results are the efficacy results of the mRNA therapeutic drug delivered by the novel lipid nanoparticles in Example 9 of the present invention. The left figure shows the mouse tumor growth curve, and the right figure shows the mouse survival curve after tumor bearing.

[0065] Fig.12 These are the analysis results of various cell subpopulations after the novel lipid nanoparticles in Example 9 of the present invention delivered mRNA to TC-1 tumor mice. DETAILED DESCRIPTION

[0066] The technical solutions provided by the present invention are described in detail below in conjunction with the examples, but they should not be understood as limiting the scope of protection of the present invention. Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials (SM-102, MC3, α-Galcer, DSPC, cholesterol and DMG-PEG2000) and reagents used can be obtained from commercial channels, and A1A3 is prepared with reference to Patent Publication No. CN114105799B.

[0067] Example 1 (A1A3-α-Galcer-LNP) (α-Galcer1.4-LNP)

[0068] This embodiment provides a novel lipid nanoparticle, the preparation raw materials of which include ionizable lipid A1A3, DSPC, cholesterol, DMG-PEG2000 and α-Galcer, and the molar ratio of each component is 46.83:9.86:40.43:1.48:1.4.

[0069] Comparative Example 1 (A1A3-LNP)

[0070] This comparative example provides a novel lipid nanoparticle, the preparation raw materials of which include ionizable lipid A1A3, DSPC, cholesterol and DMG-PEG2000, and the molar ratio of each component is 47.5:10:41:1.5.

[0071] Comparative Example 2 (MC3-LNP)

[0072] This comparative example provides a novel lipid nanoparticle, the preparation raw materials of which include ionizable lipid MC3, DSPC, cholesterol and DMG-PEG2000, and the molar ratio of each component is 47.5:10:41:1.5.

[0073] Example 2 (α-Galcer0.36-LNP)

[0074] This embodiment provides a novel lipid nanoparticle, the preparation raw materials of which include ionizable lipid A1A3, DSPC, cholesterol, DMG-PEG2000 and α-Galcer, and the molar ratio of each component is 47.33:9.97:40.85:1.49:0.36.

[0075] Example 3 (α-Galcer0.72-LNP)

[0076] This embodiment provides a novel lipid nanoparticle, the preparation raw materials of which include ionizable lipid A1A3, DSPC, cholesterol, DMG-PEG2000 and α-Galcer, and the molar ratio of each component is 47.16:9.93:40.70:1.49:0.72.

[0077] Example 4

[0078] This embodiment provides a lipid nanoparticle, the preparation raw materials of which include ionizable lipid A1A3, DSPC, cholesterol, DMG-PEG2000 and α-Galcer, and the molar ratio of each component is 45.32:9.54:39.11:1.43:4.6.

[0079] Example 5

[0080] This example provides a method for preparing the novel lipid nanoparticles described in Example 1, which is as follows: Ionizable lipid A1A3, DSPC, cholesterol, DMG-PEG2000 and α-Galcer were dissolved in anhydrous ethanol according to a fixed formula molar ratio of 46.83:9.86:40.43:1.48:1.4, i.e., the ethanol phase; the mRNA drug (sequence see SEQ1-4) was dissolved in a sodium acetate solution, i.e., the aqueous phase; the ethanol phase and the aqueous phase were respectively inserted into the two ends of the microfluidic chip with sterile syringes, and the ethanol phase and the aqueous phase were mixed using a microfluidic device to control the ratio of the volume of the ethanol phase to the aqueous phase to be 1:3, lipid nanoparticle solution. Using ultrafiltration technology, ultrafiltration was performed with PBS+20 mM Tris-HCl solution to remove ethanol and some small molecule impurities. The preparation method of the comparative example was similar, the only difference being the components and proportions. The prepared mRNA-new LNP drug is then subjected to quality control, mainly including parameters such as encapsulation efficiency, particle size, Zeta potential, RNA capillary electrophoresis and α-GalCer content. The encapsulation efficiency is greater than 90%, the particle size is about 70-100nm, the Zeta is between ±30, the polydispersity coefficient PDI is less than 0.2, the content deviation of each component in HPLC is less than 5%, and the capillary electrophoresis RNA content, i.e., the CE value, is greater than 75%.

[0081] The encapsulation efficiency, particle size, and potential parameters of the new lipid nanoparticles can be found in Figure 2 , HPLC results see Figure 3 , capillary electrophoresis results see Figure 4 .

[0082] The experimental results show that the novel lipid nanoparticles of the present invention successfully encapsulate 1.4% of α-GalCer, indicating a high encapsulation efficiency, and the particle size, potential parameters, and CE value are all within the normal range of medication specifications and meet the standards.

[0083] Example 6

[0084] This example verifies the delivery efficiency of the novel lipid nanoparticles.

[0085] 1. Obtaining bone marrow-derived dendritic cells (BMDC)

[0086] (1) C57BL / 6 mice (6-8 weeks old, weighing 20-25g) were killed by cervical dislocation and immersed in 75% alcohol for 5 minutes for disinfection. The thigh and tibia of the mouse were dissected and the ligaments and Achilles tendons connected to the joints were cut off. The muscles were removed to expose the bones. The joints at both ends were cut off. A 1 mL sterile syringe needle was aimed at the joint part, and the red bone marrow cells were blown into PBS. The cells were gently blown until no cell clumps were visible to the naked eye and the total volume was less than 10 mL. The above solution was transferred to a 50 mL centrifuge tube equipped with a 40 μm cell strainer and filtered. The filtrate was transferred to a 15 mL centrifuge tube and centrifuged at 4°C and 500 rcf for 5 minutes. The supernatant was discarded, and 2 mL of ACK red blood cell lysis buffer was added. The cells were gently blown to mix, and the cells were gently shaken for 5 minutes. 6 mL of PBS solution was added to stop the lysis. The cells were centrifuged at 4°C and 500 rcf for 5 minutes. The supernatant was discarded and 3-6 mL of the above culture medium was taken and resuspended by blowing. Take 10 μL of cell suspension in a 1.5 mL EP tube, add 10 μL of trypan blue dye, mix well, take 10 μL in a cell counting plate, count and calculate the dilution volume. Dilute the cell suspension to 1.5×10 6 cells / mL, and spread them into 6-well plates. Add 2 mL of diluted cell suspension to each well and place in a 37°C, 5% CO2 cell culture incubator. Change half of the medium every 2 days until the 6th day, when cells that do not adhere tightly are collected as BMDCs.

[0087] (2) Culture conditions: BMDCs were cultured using culture medium (1640) (supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin) and 50 ng / mL recombinant cytokine GM-CSF and 2.5 ng / mL recombinant cytokine IL-4. The cells were incubated in a cell culture incubator at 37°C, 5% CO2 and 95% humidity.

[0088] 2. Verify BMDC

[0089] (1) Morphological observation: Most BMDCs grew in colonies, and the cells had multiple dendritic processes, which were more obvious in mature BMDCs. (2) Cell phenotype analysis: Flow cytometry was used to detect the CD11c marker molecule on the surface of BMDC cells. Cells positive for CD11c were BMDCs.

[0090] The results of BMDC induction purity identification can be found in Figure 1 .

[0091] The experimental results show that the purity of DC induced by the present invention reaches 80% or more.

[0092] 3. Novel lipid nanoparticles deliver mRNA drugs to BMDCs

[0093] Novel lipid nanoparticles were prepared by referring to the method of Example 5, and the novel lipid nanoparticles were used to deliver mRNA drugs to BMDCs: on the 6th day, suspended cells and loosely attached cells were collected and inoculated into corresponding well plates, and novel lipid nanoparticles encapsulating mRNA (working concentration 1 μg / mL) were added to the cell culture well plates, which were then placed in an incubator at 37°C and 5% CO2 for 8-12 hours to complete the delivery of mRNA drugs to BMDCs.

[0094] 4. After the new nanoparticles deliver mRNA drugs to BMDCs, detect the expression level of the target molecule in the cells

[0095] (1) On the 6th day, the suspended cells and loosely attached BMDCs were collected and inoculated into a 96-well white microplate reader plate at a density of 200,000 cells per well, 6 replicates, and a culture medium volume of 100 μL. After the cells were stabilized for 2 hours, the new lipid nanoparticles encapsulating mRNA were added to the 96-well plate with BMDCs to control the Luciferase-LNP in each well (working concentration 1 μg RNA / mL). Then, the plate was placed in an incubator at 37°C and 5% CO2 for 4-12 hours.

[0096] (2) Take the plate for testing at different time points, add 20ul / well of luciferase substrate to the 96-well plate, and use an ELISA reader to detect its bioluminescence value at 150nm.

[0097] (3) Detect the level of mRNA drugs delivered by the new nanoparticles to the cell line DC2.4, using the same procedure as for BMDC, as in (1) (2).

[0098] After the novel nanoparticles delivered Luciferase-mRNA to BMDC and DC2.4, the time curve of mRNA expression in the two cells can be found in Figure 6 .

[0099] The experimental results show that the ability of mRNA-novel A1A3-α-Galcer-LNP drug to deliver Luciferase-mRNA on BMDC and DC2.4 is better than MC3 and A1A3.

[0100] 5. After the novel nanoparticles delivered the mRNA drug to BMDC, the formation of α-Galcer-CD1d complex by the fifth component α-Galcer on DC was detected

[0101] (1) On day 6, suspended cells and loosely attached BMDCs were collected and seeded into 48-well plates at a seeding density of 50,000 cells per well in a medium volume of 100 μL. New lipid nanoparticles encapsulating mRNA were added to the 48-well plates with BMDCs to control the mRNA-LNP in each well (working concentration 1 μg / mL). The plates were then placed in an incubator at 37°C and 5% CO2 for 24 hours.

[0102] (2) Collect cells, centrifuge and discard the supernatant, add PBS to resuspend the cells, centrifuge again and discard the supernatant. Use flow cytometry to detect the formation of α-Galcer-CD1d complex, OVA-mRNA expression and presentation on the cell surface, and changes in BMDC surface markers.

[0103] After the novel lipid nanoparticles were delivered into DCs, α-Galcer-CD1d complexes were generated (see results). Figure 7 ), presenting H2-Kb to the cell surface, BMDC maturation and activation, and functional results can be found in Figure 8 .

[0104] The experimental results showed that the new lipid nanoparticles can form a high level of α-Galcer-CD1d complex on DC. The new lipid nanoparticles can successfully deliver the target mRNA into the cells, and the target mRNA is expressed and presented on the cell surface. After the new lipid nanoparticles were transfected into BMDC, compared with the PBS group, BMDC surface markers such as CD40, CD69, OX40L, CD86, MHCII, etc. were upregulated, promoting DC maturation and activation; intracellular Ki67, T-Bet, IL-12, etc. were upregulated, promoting DC cell proliferation and functional activation.

[0105] Example 7

[0106] This example verifies the in vivo safety of novel lipid nanoparticles for delivering mRNA.

[0107] The mRNA drugs were delivered to mice via novel lipid nanoparticles and their organ tissues and blood biochemistry were detected.

[0108] (1) Mice (C57BL / 6 mice, 6-8 weeks old, female) were prepared and divided into groups. The mice injected with novel lipid nanoparticles to deliver OVA mRNA were used as the experimental group, the mice injected with four components of lipid nanoparticles to deliver OVA mRNA were used as the experimental control group, and the complete negative control was the mice injected with PBS.

[0109] (2) The novel lipid nanoparticles delivering OVA mRNA drugs and the four-component lipid nanoparticles delivering OVA mRNA drugs were injected intramuscularly into each group of mice. The mice were given drugs on day 0, day 3, and day 6, for a total of three times, with each mouse receiving 20 μg each time.

[0110] (3) On the 11th day, the mice were anesthetized and killed, and the heart, liver, spleen, lung, kidney and peripheral blood of the mice were collected. After the organs were fixed, HE staining experiments were performed. Serum was extracted from the peripheral blood and alanine aminotransferase, aspartate aminotransferase, urea nitrogen, and serum creatinine were tested.

[0111] For organ tissue staining and blood biochemical indicators after the new lipid nanoparticles delivered mRNA to mice, see Fig. 9 .

[0112] The experimental results showed that the new lipid nanoparticles had no obvious toxicity to C57BL / 6j mice.

[0113] Example 8

[0114] This example verifies the immunogenicity of mRNA delivered by novel lipid nanoparticles.

[0115] 1. Delivering mRNA drugs to mice via novel lipid nanoparticles to detect changes in the specific immune response of mice

[0116] (1) Mice (C57BL / 6 mice, 6-8 weeks old, female) were prepared and divided into groups. The mice injected with novel lipid nanoparticles to deliver OVA mRNA were used as the experimental group, the mice injected with four components of lipid nanoparticles to deliver OVA mRNA were used as the experimental control group, and the complete negative control was the mice injected with PBS.

[0117] (2) The novel lipid nanoparticles delivering OVA mRNA drugs and the four-component lipid nanoparticles delivering OVA mRNA drugs were injected intramuscularly into each group of mice. The mice were given drugs on day 0 and day 4, for a total of 2 times, with each mouse receiving 5 μg each time.

[0118] (3) On the 10th day, the mice were anesthetized and killed, and the spleen was removed. A single cell suspension of spleen cells was prepared and T cells were isolated.

[0119] (4) BMDCs were pre-treated with negative control PBS and OVA mRNA lipid nanoparticles, and then BMDCs were collected.

[0120] (5) After incubating BMDC and T cells isolated in step (3) on an ELISPOT plate containing IFN-γ, TNF-α or Perforin for 12 hours, the number of specific spots is detected. The number of spots represents the immunogenicity of the mRNA in specifically activating T cells to produce IFN-γ, TNF-α or Perforin.

[0121] 2. Delivering mRNA drugs to mice via novel lipid nanoparticles to detect changes in the immune response of NKT cells in mice

[0122] (1) Mice (C57BL / 6 mice, 6-8 weeks old, female) were prepared and divided into groups. The mice injected with novel lipid nanoparticles to deliver OVA mRNA were used as the experimental group, the mice injected with four components of lipid nanoparticles to deliver OVA mRNA were used as the experimental control group, and the complete negative control was the mice injected with PBS.

[0123] (2) The novel lipid nanoparticles delivering OVA mRNA drugs and the four-component lipid nanoparticles delivering OVA mRNA drugs were injected intramuscularly into each group of mice. The mice were given drugs on day 0, day 4, and day 8, for a total of 3 times, with each mouse receiving 5 μg each time.

[0124] (3) On the 11th day, the mice were anesthetized and killed, and the spleen and lymph nodes were removed and made into a single cell suspension. The mouse NKT cells and various cell subsets were detected and analyzed by flow cytometry.

[0125] The results of the analysis of various cell subpopulations after the novel lipid nanoparticles delivered mRNA to mice can be found in Fig.10 .

[0126] The experimental results show that the new lipid nanoparticles can promote the production of more NKT cells in mice and enhance some functions of CD8T and NKT cells.

[0127] Example 9

[0128] This example provides pharmacodynamic validation of a novel lipid nanoparticle-delivered mRNA drug in a cervical cancer model.

[0129] 1. Delivering mRNA drugs to cervical cancer tumor model mice via novel lipid nanoparticles to detect their therapeutic effects

[0130] (1) Prepare mice (C57BL / 6 mice, 6-8 weeks old, female) and establish a tumor model in mice subcutaneously.

[0131] (2) After the mice successfully developed subcutaneous tumors (tumor size of about 30 mm3), the mice were randomly divided into groups. The group of mice injected with the new lipid nanoparticles to deliver the cervical cancer-related antigen E7-mRNA was used as the experimental group, the group of mice injected with the four-component lipid nanoparticles to deliver the cervical cancer-related antigen E7-mRNA was used as the experimental control group, and the complete negative control was the model mouse group injected with PBS. The mice were given drugs on the 7th, 12th, and 17th days after the mice were tumor-bearing, for a total of 3 times, with each mouse being given 5 μg each time.

[0132] (3) Regularly measure the mouse tumors. The size of the mouse tumors reaches 1500mm. 3 as the experimental endpoint for mice.

[0133] (4) Collect statistical data, draw mouse tumor growth curve and mouse survival curve, and compare the therapeutic effects of each group of drugs on mouse tumors.

[0134] The efficacy results of E7-mRNA therapeutic drugs delivered by novel lipid nanoparticles can be found in Fig.11 .

[0135] The experimental results show that the E7-mRNA therapeutic drug delivered by the new lipid nanoparticles has a stronger therapeutic effect and the survival rate is increased by 30%.

[0136] 2. Delivering mRNA drugs to cervical cancer tumor model mice via novel lipid nanoparticles to detect changes in immune cell function in vivo

[0137] (1) Prepare mice (C57BL / 6 mice, 6-8 weeks old, female) and establish a tumor model in mice subcutaneously.

[0138] (2) After the mouse subcutaneous tumor is successfully formed (tumor size is about 30mm 3 ), the mice were randomly divided into groups, with the mice injected with novel lipid nanoparticles to deliver cervical cancer-related antigen E7-mRNA as the experimental group, the mice injected with four components of lipid nanoparticles to deliver cervical cancer-related antigen E7-mRNA as the experimental control group, and the complete negative control was the model mouse group injected with PBS. The mice were given drugs on the 7th, 12th, and 17th days after the mice were tumor-bearing, for a total of 3 times, with each mouse given 5μg each time.

[0139] (3) On the 16th day, peripheral blood was collected from the mice submandibularly and flow cytometry was used to detect the proportion of immune cells.

[0140] (4) When the tumor model mice in each group did not reach the experimental endpoint, that is, on the 18th day, the mice were anesthetized and dissected to obtain the mouse lymph nodes, spleen and tumor tissues, and flow cytometry was used to detect the proportion of immune cells and the function of immune cells.

[0141] The analysis results of various cell subpopulations after the novel lipid nanoparticles delivered E7-mRNA to TC-1 tumor mice can be found in Fig.12 .

[0142] The experimental results showed that in TC-1 tumor-bearing mice, three injections of the novel lipid nanoparticle-delivered E7-mRNA therapeutic drug increased NKT cell infiltration in the tumor ( Fig.12 Figure 2) shows that the proportion of NK and NKT in PBMC increased ( Fig.12 Figure 3) shows that both CD8 T cells and NKT cells in the spleen were upregulated ( Fig.12 Figure 4) shows that intracellular interferon-γ in NKT\NK\CD8 T cells in lymph nodes is upregulated ( Fig.12 (Fig. 5)).

[0143] The above-mentioned embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solution of the present invention in detail, but it cannot be understood as limiting the scope of the invention patent protection. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. Lipid nanoparticles, It is characterized in that Include: (a) Cationic lipids; (b) structural lipids; (c) helper lipids; (d) polymer-bound lipids; (e) immune adjuvants; The immune adjuvant includes a NKT agonist; The NKT agonist is selected from at least one of α-galactosylceramide or its functional derivatives; The molar percentage of the immune adjuvant in the lipid nanoparticles is 0.3-5%.

2. The lipid nanoparticle according to claim 1, It is characterized in that The molar ratio of the cationic lipid to the immune adjuvant is 30-60:1-5; preferably 45-55:1-5; and / or, the molar ratio of the structural lipid to the immune adjuvant is 15-50:1-5; and / or, the molar ratio of the helper lipid to the immune adjuvant is 5-20:1-5; and / or, the molar ratio of the polymer-bound lipid to the immune adjuvant is 1-10:1-5; Preferably, the cationic lipid is selected from MC3, SM-102, ALC0315, DOTAP, DLinDMA, DLinkC2DMA, cKK-E12, A1A3, imidazole, HGT5000, HGT5001, OF-02, DODAC, DDAB, DMRIE, DOSPA, DOGS, DODAP, DODMA and DMDMA, DODAC, DLenDMA, DMRIE, CLinDMA, CpLinDMA, DMOBA, DOcarb DAP, DLinDAP, DLincarbDAP, DLinCDAP, KLin-K-DMA, DLin-K-XTC2-DMA, HGT4003, C12-200, the cationic liposomes described in Patent Publication No. CN114105799B, and the cationic liposomes described in Patent Publication No. CN113461577B, or more thereof; preferably the cationic liposomes described in Patent Publication No. CN114105799B and / or the cationic liposomes described in Patent Publication No. CN113461577B; Preferably, the structured lipid is selected from one or more of cholesterol and its derivatives, cholesterol esters, sterol hormones, sterol vitamins and phytosterols; preferably one or more of cholesterol, cholesterol esters and phytosterols; more preferably cholesterol; Preferably, the helper lipid is selected from one or more of DSPC, DOPC, DPPG, DOPS and DOPE; preferably DSPC and / or DOPS; more preferably DSPC; Preferably, the polymer-bound lipid is selected from lipids modified with PEG or its derivatives; the relative molecular mass of the PEG or its derivatives is 2000-5000, preferably 2000, 3000, 4000 or 5000.

3. Use of the lipid nanoparticles according to claim 1 or 2 in biological immune activation; the biological immune activation includes NKT cell activation.

4. Use of the lipid nanoparticles according to claim 1 or 2 as a drug delivery carrier.

5. Nucleic acid drugs, It is characterized in that The lipid nanoparticles according to claim 1 or 2 further comprise therapeutic mRNA; the therapeutic mRNA may be selected from but not limited to E7-mRNA and OVA-mRNA; the therapeutic mRNA is encapsulated in the lipid nanoparticles; Preferably, the dosage form of the nucleic acid drug is an injection, a lyophilized agent, a spray or a patch.

6. The method for preparing the nucleic acid drug according to claim 5, Features: The lipid nanoparticles are dissolved in anhydrous ethanol to obtain an ethanol phase; the therapeutic mRNA is dissolved in water to obtain an aqueous phase; the ethanol phase and the aqueous phase are mixed to obtain the nucleic acid drug.

7. Pharmaceutical compositions, It is characterized in that The method comprises the nucleic acid drug according to claim 5, or the nucleic acid drug prepared by the preparation method according to claim 6; and further comprises: an immune checkpoint inhibitor; Preferably, the immune checkpoint inhibitor is selected from one or more of anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody and anti-LAG3 antibody.

8. Use of the lipid nanoparticles according to claim 1 or 2, or the nucleic acid drug according to claim 5, or the nucleic acid drug prepared by the preparation method according to claim 6, or the pharmaceutical composition according to claim 7 in the preparation of a drug for treating tumors; Preferably, the tumor includes at least one of cervical cancer, pancreatic cancer, renal cell carcinoma, colorectal cancer, and liver cancer.

9. The use according to claim 8, It is characterized in that Include at least one of the following: (1) The nucleic acid drug is used in combination with radical surgery to treat tumors; (2) The nucleic acid drug and chemotherapy drug are used in combination to treat tumors; (3) The nucleic acid drug and antibody-drug conjugate are used in combination to treat tumors; (4) The nucleic acid drug and the antibody-conjugated radioactive drug are used in combination to treat tumors.

Citation Information

Cited By

  • Lipid nanoparticle and application thereof

    CN119876277A